Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Induction in Islet Transplantation for Type 1 Diabetes
NCT00175253Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in type 1 diabetes mellitus (T1D), sponsored by University of Alberta. Primary endpoint: Safety of alemtuzumab induction and tacrolimus/MMF maintenance. Started Nov 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00175253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00175253.